iPS Cells & Regenerative Medicine Weekly Report May 24, 2026

Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia

iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment

SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations

The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges

iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications

iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies

CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances

NIH-Funded Breakthrough Miniaturizes CRISPR for Precision In Vivo Gene Delivery